IRIS
SANTONI, MATTEO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.763
EU - Europa 2.296
AS - Asia 856
AF - Africa 142
Continente sconosciuto - Info sul continente non disponibili 5
OC - Oceania 2
SA - Sud America 2
Totale 10.066
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.761
UA - Ucraina 466
IT - Italia 404
IE - Irlanda 388
SE - Svezia 380
SG - Singapore 266
CN - Cina 254
DE - Germania 246
TR - Turchia 176
DK - Danimarca 158
CI - Costa d'Avorio 128
FI - Finlandia 105
GB - Regno Unito 94
KR - Corea 91
IN - India 60
FR - Francia 20
BE - Belgio 18
MA - Marocco 14
EU - Europa 5
NL - Olanda 3
AU - Australia 2
BG - Bulgaria 2
ID - Indonesia 2
LU - Lussemburgo 2
RS - Serbia 2
RU - Federazione Russa 2
VN - Vietnam 2
AE - Emirati Arabi Uniti 1
AT - Austria 1
BR - Brasile 1
CA - Canada 1
CZ - Repubblica Ceca 1
ES - Italia 1
IL - Israele 1
IS - Islanda 1
MX - Messico 1
MY - Malesia 1
NP - Nepal 1
PE - Perù 1
PL - Polonia 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 10.066
Salva come PNG Salva come JPEG
Città #
Chandler 858
Fairfield 706
Des Moines 686
Jacksonville 528
Ashburn 474
Dublin 386
Wilmington 378
Boardman 321
Woodbridge 306
Seattle 269
Houston 247
New York 201
Cambridge 195
Lawrence 160
Princeton 160
San Mateo 153
Abidjan 128
Ann Arbor 126
Centro 98
San Diego 78
Singapore 78
Pune 56
Turin 38
Washington 38
Beijing 33
Marche 33
London 32
Los Angeles 27
Redmond 26
Helsinki 25
Dallas 22
Falls Church 22
Guangzhou 21
Ancona 20
Norwalk 20
Wuhan 19
Shanghai 17
Brussels 16
Jiaxing 14
Kilburn 11
Rome 10
Wuxi 9
Hounslow 8
Izmir 8
Squinzano 8
Nanjing 7
Prescot 7
Chiswick 6
Porto 6
Strasbourg 6
Yiwu 6
Seoul 5
Tolentino 5
Chengdu 4
Chicago 4
Edinburgh 4
Fayetteville 4
Frankfurt am Main 4
Shenzhen 4
Wandsworth 4
Berlin 3
Buffalo 3
Clifton 3
Jinhua 3
Macerata 3
Marano di Valpolicella 3
Milan 3
Modena 3
Phoenix 3
Portland 3
Redwood City 3
Santa Clara 3
Torre Del Greco 3
Augusta 2
Città di Castello 2
Fuzhou 2
Hanoi 2
Heze 2
Isola della Scala 2
Jesi 2
Jinan 2
Luxembourg 2
Montechiarugolo 2
Montelupone 2
Mumbai 2
Palermo 2
Rapagnano 2
San Benedetto del Tronto 2
San Biagio 2
San Severino Marche 2
Segrate 2
Sofia 2
Southwark 2
Stockholm 2
Sydney 2
Trecate 2
Waanrode 2
Arequipa 1
Ascoli Piceno 1
Atlanta 1
Totale 7.235
Salva come PNG Salva come JPEG
Nome #
Designing novel immunocombinations in metastatic renal cell carcinoma 152
Germline and somatic mutations in prostate cancer: Focus on defective DNA repair, PARP inhibitors and immunotherapy 128
Thymic neoplasms: an update on the use of chemotherapy and new targeted therapies. A literature review. 114
Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients 105
Microbiome and cancers, with focus on genitourinary tumors 105
Metabolic phenotype of bladder cancer 105
Impact of VEGF, VEGFR, PDGFR, HIF and ERCC1 gene polymorphisms on thymic malignancies outcome after thymectomy 102
Sequential or Concomitant Inhibition of Cyclin-Dependent Kinase 4/6 Before mTOR Pathway in Hormone-Positive HER2 Negative Breast Cancer: Biological Insights and Clinical Implications 102
Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in clear cell renal cell carcinoma patients 100
Bone metastases in patients with metastatic renal cell carcinoma: Are they always associated with poor prognosis? 99
Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in Renal Cell Carcinoma 98
Lgr5 expression, cancer stem cells and pancreatic cancer: Results from biological and computational analyses 97
Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer 95
KRAS mutation status is associated with specific pattern of genes expression in pancreatic adenocarcinoma 93
BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: Molecular diagnostics and possible targets for personalized therapies 93
Metabolic Alterations in Renal and Prostate Cancer 91
Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications 91
Toll like receptors and pancreatic diseases: From a pathogenetic mechanism to a therapeutic target 90
Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies 88
Is There a Role for Immunotherapy in Prostate Cancer? 88
Neutrophil‑to‑lymphocyte ratio may be associated with the outcome in patients with prostate cancer 87
Pd-l1 inhibitors for the treatment of prostate cancer 84
PD-1 blockade therapy in renal cell carcinoma: current studies and future promises 83
Hyponatremia in cancer patients: Time for a new approach 83
HER family receptor expression and prognosis in pancreatic cancer 82
Oligometastases in Genitourinary Tumors: Recent Insights and Future Molecular Diagnostic Approach 82
Hyponatremia normalization as an independent prognostic factor in patients with advanced non-small cell lung cancer treated with first-line therapy 82
Predicting future cancer burden in the United States by artificial neural networks 81
Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib 81
New prostate cancer targets for diagnosis, imaging, and therapy: Focus on prostate-specific membrane antigen 78
Exploring the Spectrum of Kidney Ciliopathies 78
Pseudocarcinomatous hyperplasia associated with primary lymphoma in the urinary bladder: a case report 78
Urinary catheters and biofilm formation 77
Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies 77
The route to personalized medicine in bladder cancer: where do we stand? 77
Epithelial to Mesenchymal Transition in Renal Cell Carcinoma: Implications for Cancer Therapy 76
Correlation of Stomatitis and Cutaneous Toxicity With Clinical Outcome in Patients With Metastatic Renal-Cell Carcinoma Treated With Everolimus 76
Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer 76
Adjuvant therapy in renal cell carcinoma: Is it the right strategy to inhibit VEGF? 76
Risk of hyponatraemia in cancer patients treated with targeted therapies: A systematic review and meta-analysis of clinical trials 74
KRAS: To be or not to be targeted? Biologic and computational analyses in pancreatic adenocarcinoma 73
Molecular characterization of testicular germ cell tumors using tissue microdissection 73
Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution 73
Metabolic alterations in renal cell carcinoma 72
Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy 72
Immunotherapy in renal cell carcinoma: latest evidence and clinical implications 72
Biomarkers for VEGF-Targeted Therapy in Renal Cell Carcinoma: Critical Review of Level of Evidence and Up to Date 71
Present and future of personalized medicine in adult genitourinary tumors 70
Impact of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) single nucleotide polymorphisms on outcome in gastroenteropancreatic neuroendocrine neoplasms 70
High CTLA-4 expression correlates with poor prognosis in thymoma patients 70
RAS genes in colorectal carcinoma: Pathogenesis, testing guidelines and treatment implications 70
Update on histopathological evaluation of lymphadenectomy specimens from prostate cancer patients 69
IMPACT OF VEGF, VEGFR, PDGFR, HIF AND ERCC1 GENE POLYMORPHISMS ON THYMIC MALIGNANCIES OUTCOME 69
Combining radiotherapy with immunocheckpoint inhibitors or CAR-T in Renal Cell Carcinoma 69
Quick steps toward precision medicine in renal cell carcinoma 69
Current and emerging bladder cancer biomarkers with an emphasis on urine biomarkers 69
Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter 69
Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer 69
Surgical Resection Does Not Improve Survival in Patients with Renal Metastases to the Pancreas in the Era of Tyrosine Kinase Inhibitors 68
Emerging concepts on drug resistance in bladder cancer: Implications for future strategies 68
Trattamento del carcinoma del pancreas. Attualità e prospettive 68
Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies 68
Real-world data on cabozantinib in previously treated patients with metastatic renal cell carcinoma: Focus on sequences and prognostic factors 68
Genitourinary tumors: Update on molecular biomarkers for diagnosis, prognosis and prediction of response to therapy 68
TNM staging towards a personalized approach in metastatic urothelial carcinoma: What will the future be like?-a narrative review 68
Pathogenic and Diagnostic Potential of BLCA-1 and BLCA-4 Nuclear Protein in Urothelial Cell Carcinoma of Human Bladder 67
Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma. 67
Neuroendocrine differentiation in prostate cancer: novel morphological insights and future therapeutic perspectives. 67
Re: Epithelial-to-mesenchymal transition in renal neoplasms 67
An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer 67
PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: the Role of PD-L1 Assay 67
Intraductal Carcinoma of the Prostate: Pathogenesis and Molecular Perspectives 67
New molecular targets in non clear renal cell carcinoma: An overview of ongoing clinical trials 67
Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer 66
The role of obesity in renal cell carcinoma patients: Clinical-pathological implications 66
New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents? 66
Emerging Immunotargets and Immunotherapies in Prostate Cancer 65
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer 65
Immunotherapy and radiation therapy in renal cell carcinoma 64
null 64
Editorial: Emerging biomarkers in genitourinary tumors 63
The identification of immunological biomarkers in kidney cancers 63
Treating prostate cancer by antibody-drug conjugates 63
AR-V7 and prostate cancer: The watershed for treatment selection? 62
Pre-treatment systemic immune-inflammation represents a prognostic factor in patients with advanced non-small cell lung cancer 62
null 62
The origin of prostate metastases: emerging insights 61
Epigenetic modulations and lineage plasticity in advanced prostate cancer 61
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma 60
Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy 60
Renal Cell Carcinoma: genomic landscape and clinical implications 60
Bone targeting agents in patients with metastatic prostate cancer: State of the art 60
Molecular characterization and diagnostic criteria of renal cell carcinoma with emphasis on liquid biopsies 59
Liquid biopsy in the clinical management of bladder cancer: current status and future developments 58
Bladder cancer: molecular determinants of personalized therapy 58
Recent aspects of Sunitinib therapy in patients with metastatic clear-cell Renal Cell Carcinoma: a systematic review of the litherature. 57
Renal cell carcinoma with rhabdoid features and loss of INI1 expression in an individual without sickle cell trait. 57
Re: Daniel M. Geynisman. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. Eur Urol 2015;68:912-4 57
Role of STAT3 pathway in genitourinary tumors 57
Healthcare cost of HER2-positive and negative breast tumors in the United States (2012–2035) 57
Totale 7.558
Salva come PNG Salva come JPEG
Categoria #
all - tutte 59.268
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 59.268
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020571 0 1 93 6 97 1 94 2 98 21 30 128
2020/20212.580 140 151 236 15 242 512 268 200 196 277 273 70
2021/20221.351 200 208 40 24 26 142 33 65 104 118 134 257
2022/20232.870 240 271 149 214 151 879 6 156 586 13 152 53
2023/20241.409 239 34 99 163 204 362 30 41 4 31 17 185
2024/2025537 330 207 0 0 0 0 0 0 0 0 0 0
Totale 10.324